The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer
World Journal of Urology · 11.04.2026 · 44 (1)
DOI: 10.1007/s00345-026-06381-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 11.04.2026. Verfasst von Baian Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical College of Guangzhou, Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: C-Reactive Protein, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Serum Albumin. Die Arbeit nennt 28 Literaturangaben. Gefördert von: the Chinese Medicine Science and Technology Research Fund of Guangdong Provincial Hospital of Chinese Medicine, Scientific and Technological Research of Traditional Chinese Medicine of Guangdong Provincial Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
BACKGROUND: The C-reactive protein-albumin-lymphocyte index (CALLY), a composite inflammatory and nutritional biomarker, has shown prognostic utility in various cancers, but its role in metastatic hormone-sensitive prostate cancer (mHSPC) remains underexplored. OBJECTIVE: To evaluate the association between baseline CALLY index and overall survival (OS) and time to castration-resistant prostate cancer (CRPC) in mHSPC patients. METHODS: In this retrospective cohort study, 192 mHSPC patients receiving first-line endocrine therapy (2017-2024) were stratified by median CALLY (30) into low-CALLY (30) and high-CALLY (≥ 30) groups. Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. Weighted Cox models assessed associations with OS and CRPC-free survival. Subgroup analyses were conducted by age group, metastatic volume and first-line mHSPC therapy. RESULTS: After IPTW adjustment, a high baseline CALLY index was identified as an independent protective factor for both clinical endpoints. Specifically, patients in the high-CALLY group had a 71% reduced risk of all-cause mortality (adjusted hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.18-0.46, p < 0.001) and a 49% reduced risk of CRPC progression (adjusted HR 0.51, 95% CI 0.34-0.77, p = 0.001), compared with the low-CALLY group. The prognostic association remained consistent across all prespecified subgroups, with pronounced benefits observed in patients with high-volume metastatic disease and those receiving first-line bicalutamide. Sensitivity analyses (treating CALLY as a continuous variable, conventional multivariable Cox regression) and E-value assessment further confirmed the robustness and independence of the findings. CONCLUSION: The CALLY index is an accessible and independent prognostic biomarker for OS and CRPC progression in mHSPC. Its integration into clinical assessment could enhance risk stratification and support personalized treatment planning, potentially improving long-term patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical College of Guangzhou, Guangzhou University of Chinese Medicine, Guangzhou, China.
- The Second Affiliated Hospital of Guangzhou, Guangzhou University of Chinese Medicine, Guangzhou, China.
- The Second Affiliated Hospital of Guangzhou, Guangzhou University of Chinese Medicine, Guangzhou, China. guoxinfeng@gzucm.edu.cn.
- The Second Affiliated Hospital of Guangzhou, Guangzhou University of Chinese Medicine, Guangzhou, China. hejunweigzy@163.com.
Förderung
- the Chinese Medicine Science and Technology Research Fund of Guangdong Provincial Hospital of Chinese Medicine
- Scientific and Technological Research of Traditional Chinese Medicine of Guangdong Provincial Administration of Traditional Chinese Medicine
Zitieren
APA
Wei, B., Chen, G., Liu, M., Gan, S., Bai, Z., Wang, Z., Guo, X., & He, J. (2026). The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-026-06381-6
Vancouver
Wei B, Chen G, Liu M, Gan S, Bai Z, Wang Z, et al. The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-026-06381-6
BibTeX
@article{Wei2026,
author = {Wei, Baian and Chen, Genghang and Liu, Mingzhu and Gan, Shu and Bai, Zunguang and Wang, Zhaohui and Guo, Xinfeng and He, Junwei},
title = {The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer},
journal = {World Journal of Urology},
year = {2026},
volume = {44},
number = {1},
doi = {10.1007/s00345-026-06381-6}
}
EUVIMED